ECMO in Myocardial Infarction-Associated Cardiogenic Shock: Blood Biomarkers as Predictors of Mortality.
Thomas SenonerBenedikt TremlRobert BreitkopfUlvi Cenk OezpekerNicole InnerhoferChristine KaindlstorferAleksandra Radovanovic SpurnicZoran BukumiricPublished in: Diagnostics (Basel, Switzerland) (2023)
In our study population of patients with myocardial infarction-associated cardiogenic shock, deceased patients had increased levels of inflammatory blood biomarkers throughout the whole study period. Increased procalcitonin levels have been associated with a higher risk of mortality. Future studies are needed to show the role of procalcitonin in patients receiving ECMO support.
Keyphrases
- heart failure
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- left ventricular
- end stage renal disease
- newly diagnosed
- ejection fraction
- risk factors
- oxidative stress
- cardiovascular disease
- type diabetes
- prognostic factors
- coronary artery disease
- patient reported outcomes
- community acquired pneumonia